In this article, we will discuss Durvalumab (Warnings-10). So, let’s get started.
The frequency and severity of immune-mediated pneumonitis in patients who did not receive definitive chemoradiation prior to Durvalumab were similar whether Durvalumab was given as a single agent in patients with various cancers in a pooled data set or in patients with ES-SCLC or BTC when given in combination with chemotherapy.